COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINE HIGH DOSE VERSUS ADJUVANTED STANDARD DOSE TRIVALENT INFLUENZA VACCINE IN ENGLAND

被引：0
|
作者：
Gibbons, I [1 ]
Davidson, C. [1 ]
Clark-Wright, J. [1 ]
Miller, C. [2 ]
Carroll, S. [1 ]
Costa, M. [3 ]
Bricout, H. [4 ]
Alvarez, F. P. [4 ]
机构：
[1] Sanofi Pasteur, Reading, Rdg, England
[2] Sanofi Pasteur, Church Crookham, Ham, England
[3] Syneos Hlth, London, Lon, England
[4] Sanofi Pasteur, Lyon, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN60
引用
收藏
页码：S554 / S554
页数：1
相关论文
共 50 条
  • [41] Relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to egg-based trivalent high dose and other egg-based vaccines
    Pelton, S.
    Postma, M.
    Divino, V.
    Mould, J.
    Dekoven, M.
    Krishnarajah, G.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 465 - 465
  • [42] COST-EFFECTIVENESS OF THE CELL-BASED QUADRIVALENT VERSUS THE STANDARD EGG-BASED QUADRIVALENT INFLUENZA VACCINE IN GERMANY.
    Cai, R.
    Eichner, M.
    Schwehm, M.
    Rajaram, S.
    Joaquin, F. M. Q.
    Lamotte, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S548 - S548
  • [43] A DYNAMIC TRANSMISSION MODEL TO ESTIMATE THE PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES
    Crepey, P.
    Skinner, L.
    Carroll, S.
    Bricout, H.
    Jacob, J.
    Largeron, N.
    Alvarez, F. P.
    Clark-Wright, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S226 - S226
  • [44] An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
    Ruiz-Aragon, Jesus
    Marquez-Pelaez, Sergio
    [J]. VACCINES, 2023, 11 (02)
  • [45] Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
    Zeevat, Florian
    Crepey, Pascal
    Dolk, F. Christiaan K.
    Postma, Arjan J.
    Breeveld-Dwarkasing, Vidya N. A.
    Postma, Maarten J.
    [J]. VALUE IN HEALTH, 2021, 24 (01) : 3 - 10
  • [46] COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM
    Zeevat, F.
    Crepey, P.
    Dolk, C.
    Postma, A. J.
    Breeveld-Dwarkasing, V. N. A.
    Postma, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S647 - S647
  • [47] Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme
    Bellier, Lucile
    Petitjean, Audrey
    Sarazu, Tatiana
    Tresierra, Julio
    Guillermo Lopez, Juan
    [J]. VACCINE, 2021, 39 (30) : 4144 - 4152
  • [48] Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis
    You, Joyce H. S.
    Ming, Wai-Kit
    Chan, Paul K. S.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (03) : 564 - 571
  • [49] QUADRIVALENT INFLUENZA VACCINE IN HONG KONG- A COST-EFFECTIVENESS ANALYSIS
    You, J.
    Ming, W.
    Chan, P.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A678 - A678
  • [50] Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina
    Van Hung Nguyen
    Vizzotti, Carla
    Uruena, Analia
    Giglio, Norberto
    Magneres, Cecilia
    Richmond, Heather
    [J]. VACCINE, 2020, 38 (20) : 3682 - 3689
12345